Patents by Inventor Todd R. Golub

Todd R. Golub has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11111296
    Abstract: The invention provides compositions and methods for treating cardiac dysfunction, particularly cachexia-associated or RAGE-associated cardiac dysfunction, using an anti-RAGE agent. The invention also provides compositions and methods for identifying therapeutic agents useful for disrupting (slowing, reducing, reversing, or preventing). The methods comprise designing or identifying agents that bind to functional sites identified on the RAGE polypeptide, wherein binding of agents to the functional site(s) inhibit RAGE-mediated cachetogenic signaling.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: September 7, 2021
    Assignees: THE BROAD INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: David K. Thomas, Todd R. Golub
  • Patent number: 11058903
    Abstract: The invention provides markers indicative of pre-cachexia, compositions and methods for identifying patients with a molecular signature indicative of pre-cachexia; a culture system that reproduces the cachetic process in cells in vitro, which facilitates the screening and identification of therapeutic agents useful for disrupting (slowing, reducing, reversing, or preventing) the progression of pre-cachexia to refractory cachexia; as well as therapeutic agents identified using the culture system of the invention.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: July 13, 2021
    Assignees: THE BROAD INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: David K. Thomas, Todd R. Golub
  • Publication number: 20210169827
    Abstract: The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of proteinopathies, particularly MUC1-associated kidney disease (ADTKD-MUC1 or MKD), Retinitis Pigmentosa (e.g., due to rhodopsin mutations), autosomal dominant tubulo-interstitial kidney disease due to UMOD mutation(s) (ADTKD-UMOD), and other forms of toxic proteinopathies resulting from mutant protein accumulation in the ER or other secretory pathway compartments and/or vesicles, among others. The disclosure also identifies and provides TMED9-binding agents as capable of treating or preventing proteinopathies of the secretory pathway, and further provides methods for identifying additional TMED9-binding agents.
    Type: Application
    Filed: January 28, 2021
    Publication date: June 10, 2021
    Applicants: THE BROAD INSTITUTE, INC., THE BRIGHAM & WOMEN'S HOSPITAL, INC., DANA-FARBER CANCER INSTITUTE, INC., Instituto Carlos Slim de la Salud, A.C.
    Inventors: Anna Greka, Moran Dvela-Levitt, Maria Alimova, Eric Lander, Todd R. Golub, Florence Wagner, Brian Chamberlain, Valeria Padovano, Joseph Growney
  • Publication number: 20200347444
    Abstract: The present invention provides compositions and methods for making and using a transcriptome-wide gene-expression profiling platform that measures the expression levels of only a select subset of the total number of transcripts. Because gene expression is believed to be highly correlated, direct measurement of a small number (for example, 1,000) of appropriately-selected transcripts allows the expression levels of the remainder to be inferred. The present invention, therefore, has the potential to reduce the cost and increase the throughput of full-transcriptome gene-expression profiling relative to the well-known conventional approaches that require all transcripts to be measured.
    Type: Application
    Filed: February 18, 2020
    Publication date: November 5, 2020
    Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, DANA-FARBER CANCER INSTITUTE, INC., THE BROAD INSTITUTE, INC.
    Inventors: JUSTIN LAMB, TODD R. GOLUB, ARAVIND SUBRAMANIAN, DAVID D. PECK
  • Patent number: 10724099
    Abstract: Methods to simultaneously test and screen multiplexed, mixed cell populations, e.g., populations comprising genetically heterogeneous cancer cells, in common conditions.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: July 28, 2020
    Assignees: The Broad Institute, Inc., Dana Farber Cancer Institute, Inc.
    Inventors: Channing Yu, Todd R. Golub
  • Patent number: 10619195
    Abstract: The present invention provides compositions and methods for making and using a transcriptome-wide gene-expression profiling platform that measures the expression levels of only a select subset of the total number of transcripts. Because gene expression is believed to be highly correlated, direct measurement of a small number (for example, 1,000) of appropriately-selected transcripts allows the expression levels of the remainder to be inferred. The present invention, therefore, has the potential to reduce the cost and increase the throughput of full-transcriptome gene-expression profiling relative to the well-known conventional approaches that require all transcripts to be measured.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: April 14, 2020
    Assignees: Massachusetts Institute Of Technology, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Justin Lamb, Todd R. Golub, Aravind Subramanian, David D. Peck
  • Publication number: 20190195862
    Abstract: The invention provides markers indicative of pre-cachexia, compositions and methods for identifying patients with a molecular signature indicative of pre-cachexia; a culture system that reproduces the cachetic process in cells in vitro, which facilitates the screening and identification of therapeutic agents useful for disrupting (slowing, reducing, reversing, or preventing) the progression of pre-cachexia to refractory cachexia; as well as therapeutic agents identified using the culture system of the invention.
    Type: Application
    Filed: December 21, 2018
    Publication date: June 27, 2019
    Applicant: THE BROAD INSTITUTE, INC.
    Inventors: DAVID K. THOMAS, TODD R. GOLUB
  • Patent number: 10191033
    Abstract: The invention provides markers indicative of pre-cachexia, compositions and methods for identifying patients with a molecular signature indicative of pre-cachexia; a culture system that reproduces the cachetic process in cells in vitro, which facilitates the screening and identification of therapeutic agents useful for disrupting (slowing, reducing, reversing, or preventing) the progression of pre-cachexia to refractory cachexia; as well as therapeutic agents identified using the culture system of the invention.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: January 29, 2019
    Assignees: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: David K. Thomas, Todd R. Golub
  • Publication number: 20180362647
    Abstract: The invention provides compositions and methods for treating cardiac dysfunction, particularly cachexia-associated or RAGE-associated cardiac dysfunction, using an anti-RAGE agent. The invention also provides compositions and methods for identifying therapeutic agents useful for disrupting (slowing, reducing, reversing, or preventing). The methods comprise designing or identifying agents that bind to functional sites identified on the RAGE polypeptide, wherein binding of agents to the functional site(s) inhibit RAGE-mediated cachetogenic signaling.
    Type: Application
    Filed: December 13, 2016
    Publication date: December 20, 2018
    Applicants: THE BROAD INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: DAVID K. THOMAS, TODD R. GOLUB
  • Publication number: 20180355033
    Abstract: The invention provides therapeutic, engineered protein/peptide compositions comprising e.g., RAGE antibodies, T-cell receptors to target a RAGE receptor (including soluble forms thereof) directly and/or via differential competition with one or more pre-cachexia and/or cachexia-associated RAGE ligands or markers.
    Type: Application
    Filed: June 10, 2016
    Publication date: December 13, 2018
    Inventors: David K. Thomas, Todd R. Golub
  • Patent number: 9890429
    Abstract: The present invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating cancer (e.g., hematological malignancies in humans). A variety of biomarker chromosomal number alterations (CNAs) and biomarkers corresponding thereto, are provided, wherein alterations in the copy number of one or more of the biomarker CNAs and/or alterations in the amount, structure, and/or activity of one or more of the biomarkers comprised within the CNAs is associated with cancer status.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: February 13, 2018
    Assignees: Dana-Farber Cancer Institute, Inc., The Broad Institute, Inc.
    Inventors: Margaret A. Shipp, Stefano Monti, Bjoern Chapuy, Scott J. Rodig, Todd R. Golub
  • Publication number: 20160305934
    Abstract: The invention provides markers indicative of pre-cachexia, compositions and methods for identifying patients with a molecular signature indicative of pre-cachexia; a culture system that reproduces the cachetic process in cells in vitro, which facilitates the screening and identification of therapeutic agents useful for disrupting (slowing, reducing, reversing, or preventing) the progression of pre-cachexia to refractory cachexia; as well as therapeutic agents identified using the culture system of the invention.
    Type: Application
    Filed: December 4, 2014
    Publication date: October 20, 2016
    Applicants: THE BROAD INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: DAVID K. THOMAS, TODD R. GOLUB
  • Publication number: 20150044676
    Abstract: Methods to simultaneously test and screen multiplexed, mixed cell populations, e.g., populations comprising genetically heterogeneous cancer cells, in common conditions.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 12, 2015
    Applicant: The Broad Institute, Inc.
    Inventors: Channing Yu, Todd R. Golub
  • Publication number: 20150004158
    Abstract: The present invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating cancer (e.g., hematological malignancies in humans). A variety of biomarker chromosomal number alterations (CNAs) and biomarkers corresponding thereto, are provided, wherein alterations in the copy number of one or more of the biomarker CNAs and/or alterations in the amount, structure, and/or activity of one or more of the biomarkers comprised within the CNAs is associated with cancer status.
    Type: Application
    Filed: February 28, 2013
    Publication date: January 1, 2015
    Inventors: Margaret A. Shipp, Stefano Monti, Bjoern Chapuy, Scott J. Rodig, Todd R. Golub
  • Publication number: 20130338092
    Abstract: This invention relates to high-throughput, semi-automated methods for identifying compounds that are effective in targeting leukemia stem cells, as well as compounds identified by those methods and uses thereof for treating leukemia.
    Type: Application
    Filed: August 16, 2013
    Publication date: December 19, 2013
    Inventors: Kimberly Hartwell, Malcolm A.S. Moore, David T. Scadden, Stuart L. Schreiber, Todd R. Golub, Benito Munoz, Benjamin L. Ebert, Andrew M. Stern, Peter G. Miller, D. Gary Gilliland, Anne Van Dyk Carpenter, David J. Logan, Joseph Negri, Nicola Tolliday, Alykhan Shamji, Siddhartha Mukherjee, Alison Stewart
  • Publication number: 20110263441
    Abstract: The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating hepatic disorders such as hepatocellular carcinoma and/or cirrhosis. A variety of informative biomarkers corresponding thereto, are provided, wherein alterations in expression relative to a control is correlated with the presence of a hepatic disorder, likelihood of survival from a hepatic disorder, and likelihood of recurrence of a hepatic disorder.
    Type: Application
    Filed: October 15, 2009
    Publication date: October 27, 2011
    Inventors: Todd R. Golub, Yujin Hoshida, Bryan C. Fuchs, Kenneth K. Tanabe, Josep M. Llovet Bayer, Augusto Villanueva
  • Publication number: 20110263693
    Abstract: Based on the discovery that celastrol and gedunin are Hsp90 inhibitors, the present invention provides novel inhibitors of Hsp90. and pharmaceutically acceptable salts, derivatives, and compositions thereof. The invention provides two classes of compounds. One class includes celastrol and its derivatives. The other class includes gedunin and its derivatives. The present invention further provides methods for treating disorders wherein Hs?90 inhibition is desired (e.g., proliferative diseases, cancer, inflammatory diseases, fungal infections, etc.) comprising administering a therapeutically effective amount of an inventive compound to a subject in need thereof. Celastrol, gedunin, and derivatives thereof are particularly useful in the treatment of prostate cancer, breast cancer, ovarian cancer, lung cancer, and leukemia.
    Type: Application
    Filed: March 30, 2007
    Publication date: October 27, 2011
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Haley Vinson-Hieronymus, Todd R. Golub, Justin Lamb, Kimberly Stegmaier
  • Publication number: 20110015080
    Abstract: The present invention is directed to novel high-throughput, low-cost, and flexible solution-based methods for RNA expression profiling, including expression of microRNAs and mRNAs.
    Type: Application
    Filed: August 27, 2010
    Publication date: January 20, 2011
    Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Todd R. Golub, Justin Lamb, David Peck, Jun Lu, Eric Alexander Miska
  • Patent number: 7501248
    Abstract: Methods identifying prostate cancer, methods for prognosing and diagnosing prostate cancer, methods for identifying a compound that modulates prostate cancer development, methods for determining the efficacy of a prostate cancer therapy, and oligonucleotide microarrays containing probes for genes involved in prostate cancer development are described.
    Type: Grant
    Filed: September 26, 2005
    Date of Patent: March 10, 2009
    Assignees: Whitehead Institute for Biomedical Research, Dana-Farber Cancer Institute, Inc.
    Inventors: Todd R. Golub, Phillip G. Febbo, Kenneth N. Ross, William R. Sellers
  • Patent number: 7324926
    Abstract: Methods and apparatus for classifying or predicting the classes for samples based on gene expression are described. Also described are methods and apparatus for ascertaining or discovering new, previously unknown classes based on gene expression. Methods, computer systems and apparatus for classifying or predicting whether a sample is treatment sensitive (e.g., chemosensitive) or treatment resistant (e.g., chemoresistant) are also provided. Classification occurs based on analysis of gene expression data from samples that have been subjected to one or more compounds.
    Type: Grant
    Filed: October 1, 2001
    Date of Patent: January 29, 2008
    Assignees: Whitehead Institute for Biomedical Research, Dana-Farber Cancer Institute, Inc.
    Inventors: Pablo Tamayo, Jane E. Staunton, Donna K. Slonim, Hilary A. Coller, Todd R. Golub, Eric S. Lander, Jill P. Mesirov